# Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

> **NCT02209792** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 284 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIBR 796 BS, 5 mg
- **DRUG:** BIBR 796 BS, 20 mg

## Key facts

- **NCT ID:** NCT02209792
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-10
- **Primary completion:** 2004-01
- **Final completion:** —
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209792, "Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02209792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*